Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily.

OBJECTIVES: To study the effect of alfacalcidol (1alpha(OH)D3) on fall risk in community-dwelling elderly men and women. DESIGN: Randomized, double-blind, placebo-controlled intervention trial. SETTING: Basel, Switzerland. PARTICIPANTS: Three hundred seventy-eight community-dwelling elderly (191 women/187 men). INTERVENTION: Participants were randomly assigned to receive 1 microg of alfacalcidol or matched placebo daily for 36 weeks. MEASUREMENTS: Serum 25-hydoxyvitamin D3 (25(OH) D,1,25-dihydroxyvitamin D3 (D-hormone), and intact parathormone (iPTH) levels were measured using radioimmunoassay at baseline and every 12 weeks. Numbers of fallers and falls were assessed using a questionnaire during each study site visit. Dietary calcium intake was assessed at baseline using a food frequency questionnaire. RESULTS: At baseline, participants had, on average, normal vitamin D and D-hormone serum levels. Over 36 weeks, alfacalcidol treatment was associated with fewer fallers (odds ratio (OR)=0.69, 95% confidence interval (CI)=0.41-1.16) than placebo. In a post hoc subgroups analysis by medians of total calcium intake, this reduction reached significance in alfacalcidol-treated subjects with a total calcium intake of more than 512 mg/d (OR=0.45, 95% CI=0.21-0.97, P=.042) but not in those who consumed less than 512 mg/d (OR=1.00, 95% CI= 0.47-2.11, P=.998). Alfacalcidol treatment was also, independent of total calcium intake, associated with a significant 37.9% reduction in iPTH serum levels (P<.0001). No cases of clinically relevant hypercalcemia were observed. CONCLUSION: Provided a minimal calcium intake of more than 512 mg/d, alfacalcidol treatment significantly and safely reduces number of fallers in an elderly community dwelling population.

Quantitative assessment of the stops walking while talking test in the elderly.

OBJECTIVE: To examine whether trunk sway and walking speed differ between elderly "stoppers" and "nonstoppers" during a shorter version of the stops walking while talking (SWWT) test-an observational assessment of impaired dual-task performance-and during a normal walking trial. DESIGN: The original SWWT test was administered on the way to the test room (over a distance of 150m). Then, subjects were asked to walk 2 trials of 8m while wearing a trunk sway measuring device strapped firmly to their lower back. For the first 8-m trial, no questions were asked (control trial). During the second 8-m trial, subjects were asked an easy question (What is your age?) after walking 2m. SETTING: Long-stay geriatric care unit in Switzerland. PARTICIPANTS: Seventeen institutionalized elderly (16 women, 1 man; mean age, 86.3y; range, 79-93y). Subjects had to be able to walk at least 150m and to understand simple questions. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: The amplitude of trunk sway angle and angular velocity in the forward-backward (pitch) and side-to-side (roll) directions and the duration of each trial were compared between the two 8-m walking trials with and without a question among subjects who did and did not come to a complete stop. RESULTS: In the original SWWT test, 4 persons stopped walking while talking, compared with 8 persons who stopped in the short (8-m) walking trial when a question was asked. Persons who stopped during the 8-m trial when a question was asked had significantly longer walking durations (by 19s) and larger trunk roll angular displacements (by 5.5 degrees ) during trials, both with and without a question. For both stoppers and nonstoppers, duration was longer during the trial when a question was asked. CONCLUSION: A fixed and brief walking distance, coupled with a single sudden question, provided an effective method of identifying subjects who stop walking while talking. These subjects are those who have slower walking speeds and more unstable trunk control in the roll plane even under normal walking conditions. Our findings support the predictive capabilities of a brief SWWT test for the unstable and fall-prone elderly, as well as the usefulness of objective trunk sway measures to identify gait instabilities.

Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community-dwelling and institutionalised elderly women.

BACKGROUND: physical mobility testing is an essential component of the geriatric assessment. The timed up and go test measures basic mobility skills including a sequence of functional manoeuvres used in everyday life. OBJECTIVES: to create a practical cut-off value to indicate normal versus below normal timed up and go test performance by comparing test performance of community-dwelling and institutionalised elderly women. SETTING AND PARTICIPANTS: 413 community-dwelling and 78 institutionalised mobile elderly women (age range 65-85 years) were enrolled in a cross-sectional study. MEASUREMENTS: timed up and go test duration, residential and mobility status, age, height, weight and body mass index were documented. RESULTS: 92% of community-dwelling elderly women performed the timed up and go test in less than 12 seconds and all community-dwelling women had times below 20 seconds. In contrast only 9% of institutionalised elderly women performed the timed up and go test in less than 12 seconds, 42% were below 20 seconds, 32% had results between 20 and 30 seconds and 26% were above 30 seconds. The 10(th)-90(th) percentiles for timed up and go test performance were 6.0-11.2 seconds for community-dwelling and 12.7-50.1 seconds for institutionalised elderly women. When stratifying participants according to mobility status, the timed up and go test duration increased significantly with decreasing mobility (Kruskall-Wallis-test: p<0.0001). Linear regression modelling identified residential status (p<0.0001) and physical mobility status (p<0.0001) as significant predictors of timed up and go performance. This model predicted 54% of total variation of timed up and go test performance. CONCLUSION: residential and mobility status were identified as the strongest predictors of timed up and go test performance. We recommend the timed up and go test as a screening tool to determine whether an in-depth mobility assessment and early intervention, such as prescription of a walking aid, home visit or physiotherapy, is necessary. Community-dwelling elderly women between 65 and 85 years of age should be able to perform the timed up and go test in 12 seconds or less.

Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial.

Specific receptors for vitamin D have been identified in human muscle tissue. Cross-sectional studies show that elderly persons with higher vitamin D serum levels have increased muscle strength and a lower number of falls. We hypothesized that vitamin D and calcium supplementation would improve musculoskeletal function and decrease falls. In a double-blind randomized controlled trial, we studied 122 elderly women (mean age, 85.3 years; range, 63-99 years) in long-stay geriatric care. Participants received 1200 mg calcium plus 800 IU cholecalciferol (Cal+D-group; n = 62) or 1200 mg calcium (Cal-group; n = 60) per day over a 12-week treatment period. The number of falls per person (0, 1, 2-5, 6-7, >7 falls) was compared between the treatment groups. In an intention to treat analysis, a Poisson regression model was used to compare falls after controlling for age, number of falls in a 6-week pretreatment period, and baseline 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D serum concentrations. Among fallers in the treatment period, crude excessive fall rate (treatment - pretreatment falls) was compared between treatment groups. Change in musculoskeletal function (summed score of knee flexor and extensor strength, grip strength, and the timed up&go test) was measured as a secondary outcome. Among subjects in the Cal+D-group, there were significant increases in median serum 25-hydroxyvitamin D (+71%) and 1,25-dihydroxyvitamin D (+8%). Before treatment, mean observed number of falls per person per week was 0.059 in the Cal+D-group and 0.056 in the Cal-group. In the 12-week treatment period, mean number of falls per person per week was 0.034 in the Cal+D-group and 0.076 in the Cal-group. After adjustment, Cal+D-treatment accounted for a 49% reduction of falls (95% CI, 14-71%; p < 0.01) based on the fall categories stated above. Among fallers of the treatment period, the crude average number of excessive falls was significantly higher in the Cal-group (p = 0.045). Musculoskeletal function improved significantly in the Cal+D-group (p = 0.0094). A single intervention with vitamin D plus calcium over a 3-month period reduced the risk of falling by 49% compared with calcium alone. Over this short-term intervention, recurrent fallers seem to benefit most by the treatment. The impact of vitamin D on falls might be explained by the observed improvement in musculoskeletal function.

Effectiveness and safety of strengthening, aerobic, and coordination exercises for patients with osteoarthritis.

Exercise has generated interest as an important nonpharmacological treatment for symptomatic osteoarthritis (OA) of the hip and knee. Effect sizes in exercise interventions are small to moderate for pain and functional improvements and are similar to those observed for improvement in pain for nonsteroidal anti-inflammatory drugs (NSAIDS). However, in contrast to NSAIDS, exercise interventions are safe and improve function through a direct effect on muscle strength and function. Both aerobic and strengthening exercises seem to be equally effective in regard to pain and function in patients with OA. In obese patients with OA, a combination of diet and exercise may be advantageous for optimal benefits in health-related quality-of-life and physical function. This article will focus on recent (September 2001-August 2002) randomized controlled trials with exercise as an intervention in patients with OA.

Rofecoxib improves quality of life in patients with hip or knee osteoarthritis.

UNLABELLED: A major goal of osteoarthritis (OA) treatment is pain management to improve function and maximise quality of life. Rofecoxib is a highly selective inhibitor of cyclooxygenase-2 used in symptomatic treatment of inflammation and pain in patients with osteoarthritis of the hip or knee. AIM: The primary aim of this study was to assess the effects of rofecoxib on quality of life in elderly patients with painful osteoarthritis flares of the hip or knee, who were not responsive to or had adverse reactions to previous NSAID therapy. In addition the switch pattern of NSAIDs in these patients was recorded. METHODS: A 3-week prospective open label multicentre study with rofecoxib 25 mg daily in 134 male and female outpatients with painful osteoarthritis flares of the knee or the hip (mean age 69 years, SD + 8). On day 1 the patients were all switched from their previous NSAID to rofecoxib, followed by continuous daily treatment with rofecoxib 25mg daily over 3 weeks. On day 21 the patients discontinued daily treatment with rofecoxib and had the choice between either staying on rofecoxib, switching back to their previous NSAID, trying another NSAID or stopping drug treatment. The impact on quality of life was measured by the difference in SF-12 between day 0 and day 21. Further endpoints included changes in self-reported pain, stiffness and functional ability as measured by the WOMAC index (Western Ontario McMaster Universities Osteoarthritis Index). Correlation studies were performed between the WOMAC pain subscale and quality of life as measured by the SF-12 at baseline and over the course of the study. Patients' report of general health status and overall assessment of pain intensity, as measured by visual analogue scale (VAS), was correlated with physicians' and patients' assessment of the efficacy of rofecoxib treatment. RESULTS: Quality of life improved with rofecoxib: the physical component summary score (SF-12 PCS) was improved by a statistically significant +16.2% (p <0.0001) after 3 weeks, while the mental health component summary score (MCS) was improved by +3.0% (n.s.). Disease-specific symptoms measured by the WOMAC questionnaire were significantly improved under rofecoxib after 3 weeks: pain decreased by 29% (p <0.0001) and stiffness by 25% (p <0.0001), while functional ability increased by 24% (p <0.0001). The improvement in SF-12 PCS correlated negatively with the decrease in WOMAC scores (r = -0.54, p <0.0001; r = -0.46, p <0.0001 and r = -0.64, p <0.0001 respectively). General health was significantly improved by +30.5% (or 15.96 mm, p <0.0001) between baseline and day 21, while pain was significantly reduced by -35.2% (or 17.67 mm, p <0.0001) on the VAS scales. At the end of the 3-week study 75% of the patients and 84% of the treating physicians rated the efficacy of rofecoxib from good to excellent. Two weeks after study end the planned telephone survey revealed that 54% of the patients preferred to stay on therapy with rofecoxib, 19% had decided to switch back to their previous NSAID (this observation being most marked for diclofenac, where 38% of initial diclofenac patients had decided to switch back to their initial therapy), 9% had been switched to another NSAID and 7.5% had discontinued treatment. The switch pattern is unknown in the remaining 7.5%. CONCLUSION: Rofecoxib significantly improves quality of life, as measured by the SF-12, in OA patients who were either unresponsive to or presented with adverse reactions to previous NSAID therapy (including celecoxib). In addition, rofecoxib significantly improved pain, stiffness and function, as assessed by the WOMAC questionnaire.